Phase I/II Clinical Study to Evaluate VB15010 Tablets in Patients With Advanced Solid Tumors

Recruiting now · Phase 1/Phase 2

Conditions studied: Cancer, Neoplasms, Neoplasms, Breast, Tumor, PARP, Ovarian Neoplasms, Prostatic Cancer, Pancreatic Cancer, Breast Cancer, Biliary Cancer, Colorectal Cancer

In brief

This research is designed to determine if experimental treatment with PARP1 inhibitor, VB15010 is safe, tolerable, and has anti-cancer activity in patients with advanced solid tumors.

Key facts

Study ID

NCT06819215

Run by

Zhejiang Yangli Pharmaceutical Technology Co., Ltd.

People needed

188

Starts

2024-10-30

Expected to finish

2026-03-30

Last updated by the study team

2025-02-11

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age ≥ 18 at the time of screening;
• Histological or cytological confirmation of advanced malignancy ;
• Progressive cancer at the time of study entry;
• Adequate organ and marrow function as defined by the protocol;
• Homologous recombination repair gene mutation.

You may not qualify if…

• Major surgery within 4 weeks of the first dose of study treatment.
• Spinal cord compression or brain metastases unless asymptomatic, treated and stable and not requiring continuous corticosteroids at a dose of >10mg prednisone/day or equivalent for at least 4 weeks prior to start of study treatment. Patients with leptomeningeal carcinomatosis are excluded.
• Patients with myelodysplastic syndrome/acute myeloid leukaemia or with features suggestive of myelodysplastic syndrome (MDS)/acute myeloid leukaemia (AML).

Where it is running

• Cancer Hospital of Shandong First Medical university — Jinan, Shandong, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.